The story of Viagra and its originator, copyright, presents a tangled picture for potential investors. While the revolutionary drug initially generated enormous earnings, its protection has ended, leading to generic versions flooding the landscape . This reduction in cost presents a real hurdle for copyright and any fund considering a large stak… Read More